You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
The team published data on Monday highlighting its microfluidic chip's ability to help predict the clinical outcomes of glioblastoma patients.
A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.
The experts said that antibody testing cannot indicate an individual's immunity or help with return-to-work schemes but have use for public health agencies.
At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.
The ALARM Partnership is being launched to measure the impact of AlloSure and RemoTraC on lung transplant patients.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.
Funded by a five-year, $3.7 million NIH grant, the firm plans to offer an assay that is cheaper and less invasive than standard upper endoscopies.